Circulating tumor DNA as a noninvasive biomarker in patients with Non-Hodgkin Lymphoma (NHL)

Recruiting

• Conditions: C83.3; C85; Diffuse large B-cell lymphoma; Other and unspecified types of non-Hodgkin lymphoma

• Registration Number: DRKS00024180
• Lead Sponsor: niversitätsklinikum Freiburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Consenting patients with histologically confirmed non-Hodgkin lymphoma.

Exclusion Criteria

Minors, nursing mothers, pregnant women, patients not capable of giving consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Detection rate of tumor mutations in ctDNA in blood plasma at recurrence / progression.

Secondary Outcome Measures

Name	Time	Method
1. quantity of ctDNA: correlation of the amount of ctDNA in blood plasma with the radiologically determined tumor burden at half and after completion of therapy.<br><br>2. PFS and OS: association of the amount of ctDNA in blood plasma at the halfway point and after the completion of therapy with PFS and OS.